Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Edwin M. Posadas Clear advanced filters

  • Prostate-specific membrane antigen (PSMA) as a theranostic agent is driving changes in prostate cancer including both clinical development of new drugs and clinical care. The sensitivity of PSMA imaging has created impatience in industry and the clinic alike to replace traditional computed tomography and bone scan in clinical practice and drug development. However, the success of PSMA as a therapeutic target might limit the ability of PSMA imaging to adequately define prostate cancer in a therapeutic landscape where highly effective PSMA-based therapies are used early in the disease course.

    • Melissa L. Abel
    • Adam Sharp
    • Ravi A. Madan
    Comments & Opinion
    Nature Reviews Urology
    P: 1-3

  • Use of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall clinical benefit of the neoadjuvant use of toxic drugs, such as axitinib, has not yet been demonstrated.

    • Edwin M. Posadas
    • Robert A. Figlin
    News & Views
    Nature Reviews Urology
    Volume: 11, P: 254-256

  • It is known that there are sex differences in the incidence and prognosis of certain cancers, including melanoma. In this study, the authors utilize a melanoma model to reveal that castrated mice have a higher metastatic burden associated with androgen dependent impaired neutrophil function.

    • Janet L. Markman
    • Rebecca A. Porritt
    • Moshe Arditi
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-15

  • Renal medullary carcinoma has been almost exclusively diagnosed in patients with sickle cell anemia. O'Donnell et al. present a case of this rare and aggressive cancer in an adult with no detectable hemoglobinopathies. They describe both the histopathological features of the disease, and the systemic chemotherapies used to treat it.

    • Peter H. O'Donnell
    • Ana Jensen
    • Hikmat Al-Ahmadie
    Reviews
    Nature Reviews Urology
    Volume: 7, P: 110-114

  • Extracellular vesicles (EVs) are present in circulation at relatively early stages of disease, providing potential opportunities for early cancer diagnosis. Here, the authors report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific EV purification system for early detection of HCC by performing digital scoring on the purified EVs.

    • Na Sun
    • Yi-Te Lee
    • Yazhen Zhu
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-12

  • This Review provides an overview of the molecular determinants of renal cell carcinoma, how understanding the underlying mechanisms of disease has fuelled the development of targeted therapies, and tools to assess the value of these agents.

    • Edwin M. Posadas
    • Suwicha Limvorasak
    • Robert A. Figlin
    Reviews
    Nature Reviews Nephrology
    Volume: 13, P: 496-511

  • Recently, several therapeutic strategies in prostate cancer have been granted regulatory approval based on progression-free survival benefits alone, which is a relative change in the therapeutic development of prostate cancer treatments. Previously, overall survival was a requirement for approvals. Whether this approach is warranted or beneficial to patients remains unclear.

    • Ravi A. Madan
    • Edwin M. Posadas
    • Richard J. Lee
    Comments & Opinion
    Nature Reviews Urology
    Volume: 21, P: 646-648

  • Genetic and ancestral factors, molecular pathways involving androgen and non-androgen receptor signalling, inflammation, epigenetics, the tumour microenvironment and tumour metabolism are posited as biological factors that potentially contribute to racial disparities in Black men with prostate cancer.

    • Jun Gong
    • Daniel M. Kim
    • Stephen J. Freedland
    Reviews
    Nature Reviews Urology
    Volume: 21, P: 274-289